3rd generation weight management peptide

Retatrutide is a next-generation investigational peptide designed as a multi-receptor agonist targeting GLP-1, GIP, and glucagon pathways. This unique profile makes it one of the most promising compounds in the field of metabolic and weight management research. By simultaneously engaging multiple hormonal receptors, Retatrutide demonstrates potent effects on appetite regulation, energy expenditure, and glucose balance.
Researchers are particularly interested in its potential to support significant body weight reduction and improved metabolic health, while also exploring its impact on cardiovascular and liver-related parameters. Because of its broad receptor activity, Retatrutide is considered a step beyond traditional GLP-1 analogues, offering a new horizon for studies in obesity and related conditions. Compared to dual agonists such as Tirzepatide and single-pathway compounds like Semaglutide, Retatrutide represents a broader multi-pathway research model. For a detailed comparison of incretin-based compounds, see our GLP-1 metabolic research guide.

Research applications (investigational)

Retatrutide has been investigated in preclinical and experimental settings for its involvement in:

Multi-receptor incretin signaling (GLP-1, GIP, glucagon)
Glucose regulation and metabolic pathway interaction
Energy balance and appetite signaling mechanisms
Hepatic metabolic regulation and lipid signaling pathways
Endocrine system modeling involving multi-pathway activation
Comparative analysis of single, dual, and triple agonist compounds

These areas reflect ongoing scientific investigation into complex metabolic signaling rather than established applications.

Product characteristics

Purity: ≥ 99% (HPLC)
Appearance: white lyophilized powder
Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight: 4731.33±1.0
Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(α-Me-Leu)-Leu-Asp-Lys-(diacid-C20-γ-Glu-(AEEA)-Lys)-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Storage: store lyophilized powder at -20°C, protect from light and moisture. Reconstituted solution should be kept at 2–8°C and used within a short period.

Independent third-party verification

This batch has undergone additional third-party analytical verification through Janoshik Analytical
Batch: RT10-260410
Internal HPLC purity: 99.17%
Third-party verification: 99.57% independently confirmed high purity and identity consistency. View third-party verification.

Why choose our Retatrutide

≥ 99% purity verified by HPLC.
Produced in GMP-compliant facilities under strict QC protocols.
Each batch carefully lab tested after production (you can find Certificate of Analysis under product pictures).
Freeze-dried (lyophilized) for maximum stability and extended shelf life.
Sealed in sterile vials, ready for reconstitution.
Reconstitution: Must be reconstituted with bacteriostatic water before use. GLP-1 class peptides are sometimes slow to dissolve and require very gentle reconstitution to avoid foaming or remaining slightly cloudy.

Selected research references

Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 2023.
Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet, 2023.
Doggrell SA. Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opinion on Investigational Drugs, 2023.
Ramsbacher N et al. Retatrutide. Journal of the American Pharmacists Association, 2024.
ClinicalTrials.gov Identifier: NCT04881760 — Phase 2 study of retatrutide in obesity and overweight research models.

Related research context

Retatrutide is part of the GLP-1/GIP/glucagon triple-receptor agonist metabolic research class. For mechanistic comparison with single and dual agonists, see our GLP-1 metabolic research guide.

Browse all compounds in the Metabolic research category.

Researchers comparing multi-receptor activation may also examine:

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer
This product is sold for research purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Buyer assumes full responsibility for proper handling and use.

retatrutide

Retatrutide 10 mg